Introduction {#ss1}
============

Crohn\'s disease (CD) is a chronic inflammatory disorder of the bowel. The cause of CD is unclear and a complex interplay between genetic, environmental and immune components has been implicated.[^1^](#b1){ref-type="ref"} The prevailing hypothesis for the pathogenesis of CD is that an aberrant immune response, generated against microbial agents in genetically susceptible hosts, results in chronic intestinal inflammation. Thus far, 71 genes have been implicated in CD based on genome‐wide association studies, and include genes involved in autophagy, maintenance of mucosal barrier integrity and immune regulation.[^2^](#b2){ref-type="ref"}, [^3^](#b3){ref-type="ref"} The *NOD2/CARD15* on chromosome 16 was the first locus implicated, mutations of which are thought to affect bacterial recognition.[^4^](#b4){ref-type="ref"} Subsequently, four genes, *IL10RA, IL10RB, PSMG1* and *TNFRSF6B*, have been linked to pediatric CD.[^5^](#b5){ref-type="ref"}, [^6^](#b6){ref-type="ref"} The polygenic nature of CD suggests that direct targeting of individual disease susceptibility genes is unlikely to be therapeutically effective. Key molecules in pathophysiology, downstream of regulatory events induced by different causative factors are more likely targets for therapeutic interventions.

Insights into key gene‐environmental interactions relevant to disease pathogenesis could help identify causative stimuli (e.g. infectious agents) based on molecular signatures of the host response.[^7^](#b7){ref-type="ref"} To date, microarray studies carried out on intestinal tissue of CD patients have identified several molecular biomarkers relating to inflammation, abnormal immunoregulation and cell biology, metabolism, signaling, transcription, electrolyte transport and extracellular matrix structure.[^8^](#b8){ref-type="ref"}, [^9^](#b9){ref-type="ref"}, [^10^](#b10){ref-type="ref"}, [^11^](#b11){ref-type="ref"}, [^12^](#b12){ref-type="ref"}, [^13^](#b13){ref-type="ref"}, [^14^](#b14){ref-type="ref"}

The suppressive subtractive hybridization (SSH) technique provides a complementary, non‐biased approach to the identification of new genes or pathogens associated with CD. In SSH, suppression PCR normalizes the representation of rare and abundant cDNA within the target population, and the subtraction step removes common nucleic acid sequences between the target specimen and its matched control. This results in an enriched pool of sequences specific to the target population.[^15^](#b15){ref-type="ref"} The advantage of this approach is that no assumed knowledge of gene identity is required, as it does not rely on a defined set of gene library or conserved sequence signatures as probes for gene identification.[^7^](#b7){ref-type="ref"} Hence SSH complements microarray studies by identifying potentially important genes that may not be represented on the array platforms utilized by inflammatory bowel disease (IBD) microarray studies. SSH has been successfully used in the discovery of novel viruses, and the transcriptome profiling of human hepatoma and bone regeneration.[^16^](#b16){ref-type="ref"}, [^17^](#b17){ref-type="ref"}, [^18^](#b18){ref-type="ref"}

In the present study, we used SSH to analyze the differential expression profile in ileal biopsies from children with CD compared with age‐ and sex‐matched non‐IBD control children. The purpose of this study was to examine the initial events occurring during CD pathogenesis.

Methods {#ss2}
=======
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**Tissue selection. ** Ileal biopsy specimens (3--6 mm^3^) were obtained from patients (aged 4--16) with symptoms suggestive of IBD and undergoing initial diagnostic endoscopy at the Royal Children\'s Hospital, Melbourne, Australia. All tissue specimens were stored in RNAlater (Ambion, Melbourne, Australia) at −70°C until nucleic acid extraction. The diagnosis of CD was established using standard clinical endoscopic and histopathological criteria according to the Montreal classification.[^19^](#b19){ref-type="ref"} Patients with esophagitis, mild non‐specific gastritis or no known pathological diagnosis were used as non‐IBD controls. None of the patients had received antibiotics or immunosuppressive drugs prior to endoscopy. Demographic and clinical details of patients assayed by suppressive subtractive hybridization and real‐time reverse transcription polymerase chain reaction (RT--PCR) are presented in [1](#t1){ref-type="table"}, [2](#t2){ref-type="table"}, respectively.

###### 

Demographics, clinical details and genotype of pediatric patients assayed by suppressive subtractive hybridization

  Patient   Sex   Age at   Montreal     Diagnosis                   Endoscopic             NOD2[^§^](#t1n3){ref-type="fn"}   NOD2[^§^](#t1n3){ref-type="fn"}   NOD2[^§^](#t1n3){ref-type="fn"}   IL23[^§^](#t1n3){ref-type="fn"}   ATG16L1[^§^](#t1n3){ref-type="fn"}   TLR4[^§^](#t1n3){ref-type="fn"}
  --------- ----- -------- ------------ --------------------------- ---------------------- --------------------------------- --------------------------------- --------------------------------- --------------------------------- ------------------------------------ ---------------------------------
  CD‐SSH1   F     10.1     A1/L2/B1     CD                          Uninflamed             DEL                               CC                                GG                                GG                                CT                                   GA
  CD‐SSH2   M     14.5     A1/L1+4/B1   CD                          Inflamed, uninflamed   DEL                               CC                                GG                                GG                                CC                                   AA
  CD‐SSH3   F     12.8     A1/L3+4/B1   CD                          Inflamed               C.DEL                             CT                                GG                                GG                                TT                                   AA
  CD‐SSH4   M     13.3     A1/L3/B1     CD                          Inflamed               DEL                               CT                                GG                                GG                                CT                                   AA
  N‐SSH1    F     17       --           Mild gastritis              Uninflamed             DEL                               CT                                GG                                GG                                TT                                   AA
  N‐SSH2    F     10.9     --           No pathological diagnosis   Uninflamed             DEL                               CT                                GG                                GG                                CT                                   AA
  N‐SSH3    M     15.8     --           No pathological diagnosis   Uninflamed             DEL                               CC                                GG                                GG                                TT                                   AA
  N‐SSH4    M     10.7     --           Esophagitis                 Uninflamed             DEL                               CC                                GG                                GG                                CT                                   AA

A1 age ≤ 16 years old; L1 ileal location, L2 colonic, L3 ileocolonic, L4 upper gastrointestinal, B1 non‐stricturing, non‐penetrating; P perianal disease modifier.

Endoscopic presentation of ileal region where biopsy is taken. Where two biopsies taken from separate ileal locations of a patient differ in presentation, both are described here.

Genotyping of patients based on single‐nucleotide polymorphism were performed for an earlier study.[^20^](#b20){ref-type="ref"} Major alleles are DEL, C, G, G, C and A; for NOD2 Leu1007FsinC, Arg702Trp, Gly908Arg; IL23, ATG16L1 and TLR4 respectively.

CD, Crohn\'s disease; SSH, suppressive subtractive hybridization.

###### 

Demographics and clinical details for pediatric patients assayed by real‐time reverse transcription polymerase chain reaction

  Patient   Sex   Age at diagnosis (years)   Ileal biopsy endoscopic presentation[^†^](#t2n1){ref-type="fn"}   Histology                                                   Montreal class[^‡^](#t2n2){ref-type="fn"}
  --------- ----- -------------------------- ----------------------------------------------------------------- ----------------------------------------------------------- -------------------------------------------
  CD                                                                                                                                                                       
   CD1      M     14.6                       Unaffected                                                        Extensive ulceration                                        L3 B1
   CD2      F     10.4                       Affected                                                          Complete loss of villi, extensive neutrophil infiltration   L3 B1 P
   CD3      M     14.7                       Affected                                                          Occasional neutrophil infiltration                          L3+4 B1 P
   CD4      M     11                         Unaffected                                                        Occasional neutrophil infiltration                          NA
   CD5      M     11.7                       Unaffected; Affected                                              Moderate neutrophil infiltration                            L3 B1 P
   CD6      F     8.3                        Unaffected; Affected                                              Ulceration and granulation                                  L3+4 B1 P
   CD7      M     12                         Unaffected                                                        Normal villous architecture                                 NA
   CD8      M     9.6                        Affected                                                          Neutrophilic infiltration, crypt abscesses                  L3+4 B2 P
   CD9      M     13.8                       Unaffected                                                        Focal clusters of neutrophils, occasional granuloma         L3+4 B1 P
   CD10     M     11.6                       Unaffected                                                        Several granulomas                                          L3 B1 P
   CD11     F     13.4                       Unaffected; Affected                                              Extensive ulceration                                        L3 B3 P
   CD12     F     12.9                       Affected                                                          Moderate eosinophilic infiltration                          L3+4 B1
   CD13     M     12.8                       Affected                                                          Extensive leukocyte infiltration, extensive ulceration      L3+4 B1 P
  Non‐IBD                                                                                                                                                                  
   N1       F     10.8                       Unaffected                                                        Normal villous architecture                                 --
   N2       M     12                         Unaffected                                                        Normal villous architecture                                 --
   N3       M     7.6                        Unaffected                                                        Normal villous architecture                                 --
   N4       M     13.8                       Unaffected                                                        Normal villous architecture                                 --
   N5       F     11.1                       Unaffected                                                        Normal villous architecture                                 --
   N6       M     13.5                       Unaffected                                                        Normal villous architecture                                 --
   N7       M     4.9                        Unaffected                                                        Normal villous architecture                                 --
   N8       M     13.7                       Unaffected                                                        Normal villous architecture                                 --
   N9       F     13.5                       Unaffected                                                        Normal villous architecture                                 --

Endoscopic presentation of ileal region where biopsy is taken. Where two biopsies taken from separate ileal locations of a patient differ in presentation, both are described here.

A1 age ≤ 16 years old; L1 ileal location, L2 colonic, L3 ileocolonic, L4 upper gastrointestinal, B1 non‐stricturing, non‐penetrating B2 stricturing, B3 penetrating; P perianal disease modifier.

CD, Crohn\'s disease; IBD, inflammatory bowel disease.
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**Sample preparation and RNA extraction. ** Each biopsy was mechanically homogenized, the supernatant harvested, and RNA extracted using the AllPrep DNA/RNA Mini Kit (Qiagen, Melbourne, Australia) according to the manufacturer\'s protocol. All extractions were conducted in a biological safety cabinet class II.
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**Suppressive subtractive hybridization. ** The CD‐specific subtractive library was constructed using the PCR‐Select cDNA Subtraction Kit according to the user manual provided (Clontech, Palo Alto, CA, USA). An overview of the SSH technique is described in Figure S1. Ileal RNA were obtained separately from four CD and four non‐IBD patients, then pooled into CD and non‐IBD groups for the SSH assay. The patient groups were matched based on sex, mean age and common genotypes associated with CD, to minimize heterogeneity.
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**Differential screening. ** The library of differentially expressed cDNA specific to the CD population was constructed using the TOPO TA cloning kit (Invitrogen, Melbourne, Australia). Five thousand randomly selected clones from the CD‐specific subtractive library were spotted onto Hybond nylon membrane (Amersham Biosciences, Sydney, Australia) in 384 × 3 by 2 arrays by the Australian Genome Research Facility (AGRF), Melbourne. CD‐specific sequences were detected by reverse hybridization with digoxigenin (DIG)‐labeled probes (Roche, Sydney, Australia) synthesized directly from cDNA of the CD and non‐IBD subtractive library, according to manufacturer\'s protocol (DIG applications manual for filter hybridization, Roche). Clones with greater than three times hybridization affinity to the CD‐library‐specific probes as compared to non‐IBD‐library‐specific probes were selected for sequencing.
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**Sequence identification and data analysis. ** Sanger sequencing of differentially expressed clones was performed using an ABI 3730 DNA analyzer (Applied Biosystems, Melbourne, Australia) at the AGRF, Melbourne. The ChromasPro software (Technelysium, Brisbane, Australia) was used to remove adaptor and vector sequences, and sequences were blasted against GenBank (<http://www.ncbi.nlm.nih.gov/BLAST>). Annotated sequences were submitted to SOURCE (<http://smd.stanford.edu/cgi-bin/source/sourceBatchSearch>), where all gene symbols and chromosome locations were obtained.[^21^](#b21){ref-type="ref"} Functional assignment was determined using the University of California, Santa Cruz (UCSC) genome browser and National Center for Biotechnology Information (NCBI) Entrez Gene database.[^22^](#b22){ref-type="ref"} Ingenuity Systems\' IPA software (Ingenuity Systems Inc., <http://www.ingenuity.com>) was used to group the differentially expressed genes into biologically relevant networks.
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**Quantitative real‐time RT--PCR. ** Expression of selected human genes (*REG1A, MMP2* and *ANPEP*) in ileal biopsy was analyzed using quantitative real‐time RT--PCR. Commercially available clones from OriGene (RPL32: SC119501, MMP2: SC321560, ANPEP: SC119422, REG1A: SC122637) were used for real‐time RT--PCR method establishment. First strand cDNA was synthesized using the Superscript III RT kit (Invitrogen) according to manufacturer\'s instructions. Oligonucleotide primers spanning two different exons of each target gene were selected based on published sequences or designed using Primer3 Output software to avoid amplifying genomic DNA.[^23^](#b23){ref-type="ref"} The primers used are detailed in Table S1.

Quantification of cDNA by real‐time PCR was performed using the SYBR GreenER qPCR Super mix for ABI PRISM (Invitrogen), in accordance with manufacturer\'s instructions. Analysis of real‐time RT--PCR reactions and quantification of RNA was determined using the 7300 System Sequence Detection Software Version 1.4 (Applied Biosystems). Each sample was analyzed in triplicate. Gene expression levels for individual patient samples were normalized relative to the expression of ribosomal protein L32 (RPL32) housekeeping gene. Calculations were based on the Pfaffl method, a mathematical method based on the real‐time PCR efficiencies.[^24^](#b24){ref-type="ref"} The OriGene clone cDNA (125 fg) of each gene was used as the calibrator in every assay to allow for direct comparison of gene expression for all samples analyzed across multiple assays.
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**Statistical analysis. ** The Mann--Whitney *U*‐test was used to compare the difference in median values between gene expression in CD and non‐IBD patient samples. A *P*‐value of less than 0.05 was considered statistically significant. All statistical tests were performed using SigmaStat, version 3.5 (SyStat Software Inc., San Jose, CA, USA).
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**Ethical considerations. ** This study received ethics approval from the Human Ethics Committee of the Royal Children\'s Hospital (EHRC no. 23003). Written and informed consent was obtained from each individual, parent or guardian prior to enrolment in the study.

Results {#ss11}
=======
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**Functional classification of differentially expressed genes specific to Crohn\'s disease ileum. ** Sequence analysis of 1000 differentially expressed clones from the CD subtraction library identified 863 clones with high homology to GenBank sequences. These included 430 clones, which had matches to human mRNA sequences representing 75 annotated genes. The remaining clones had sequence similarity to mitochondrial and ribosomal genes, hypothetical proteins, expressed sequence tag (EST), human chromosomes, bacterial and animal genes.

The 75 annotated genes were assigned to eight functional clusters based on information obtained from the UCSC genome browser and NCBI Entrez Gene database. The map location, gene function and frequency of SSH clone representation for each gene is listed in Table S2. We noted an enrichment of immune function genes and inflammatory mediators (Cluster I and II); extracellular matrix, remodeling, and ion transport coding genes (Cluster III); metabolic enzymes and signal transducers (Cluster IV); genes involved in cell‐cycle regulation (Cluster V); cancer‐related genes (Cluster VI); transcription factors and post‐transcription modifiers (Cluster VI) and genes with unknown function (Clusters VIII).
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**Real‐time RT--PCR confirmation of SSH results. ** To assess the quality of the SSH data, genes representing different clone abundance levels were selected for real‐time RT--PCR quantification on ileal biopsies. Three genes were selected based on their representation of the SSH detection frequency range (high: \> 50; moderate: 10--50; low: \< 10), and also on potential functional interest with respect to CD pathogenesis. *REG1A* (55 clones) was selected based on its cell proliferative function and earlier reports of upregulation in colonic tissue of adult CD patients.[^11^](#b11){ref-type="ref"}, [^12^](#b12){ref-type="ref"} *MMP2* (12 clones) is involved in wound healing and has been proposed to have a protective role in colitis by regulating barrier function and vascularisation.[^25^](#b25){ref-type="ref"} *ANPEP* (2 clones) has previously been reported to be a receptor for coronavirus.[^26^](#b26){ref-type="ref"}

Real‐time RT--PCR analysis of the three genes was conducted on ileum‐derived RNA from 13 CD and nine non‐IBD patients, in triplicate. For CD patients CD5, CD6 and CD11, biopsies taken from both endoscopically affected and unaffected ileal locations were used in the analysis. Individual gene expression levels for each sample were represented as fold change ratios relative to the expression of positive controls (OriGene clones for *MMP2*, *ANPEP* and *REG1A*). The individual expression levels (fold change value) of each gene for the biopsy samples of the 13 CD and nine non‐IBD patients are depicted in [Figure 1](#f1){ref-type="fig"}.

![The relative expression levels of *REG1A*, *MMP2* and *ANPEP* in ileal biopsies from 13 Crohn\'s disease (CD) and nine non‐inflammatory bowel disease (IBD) patients. The relative expression ratio of each gene was calculated based on real‐time reverse transcription polymerase chain reaction (RT--PCR) efficiency and the crossing point deviation of the target patient sample versus the internal *RPL32* control, according to Pfaffl.[^24^](#b24){ref-type="ref"}](JGH-27-1083-g001){#f1}

Using the Mann--Whitney statistical test for non‐parametric and unpaired populations, the transcript expression levels of *MMP2* were found to be significantly higher in CD ileal biopsies as compared to non‐IBD ileal biopsies (*P* = 0.001). The CD population had a trend towards a higher level of *REG1A* transcript expression, although the difference was not statistically significant (*P* = 0.063). There was no significant difference in *ANPEP* transcript expression between CD and non‐IBD patient samples (*P* = 0.305). The real‐time RT--PCR results validated that genes represented by \> 10 clones enriched by subtractive hybridization were expressed in higher abundance in CD as compared with non‐IBD ileal biopsies.
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***REG1A*, *MMP2* and *ANPEP* expression. ** Analysis of *REG1A*, *MMP2* and *ANPEP* gene expression across the CD patient samples revealed interesting patterns of expression. Using a fold change ratio of 1 as reference, four CD ileum samples (CD1, CD2, CD8, CD11un) with high levels of *MMP2* expression, had low or negligible *REG1A* and *ANPEP* expression ([Fig. 1](#f1){ref-type="fig"}). This inverse pattern of expression was also observed in the CD ileum samples where *MMP2* gene expression was high.
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**Comparison of the CD expression profile represented in the SSH library with published microarray data. ** To contextualize our SSH findings, we compared our results with the data tables from seven microarray studies published previously, that had reported differential expression of genes between inflamed biopsies of CD and non‐inflamed biopsies of non‐IBD controls.[^8^](#b8){ref-type="ref"}, [^9^](#b9){ref-type="ref"}, [^10^](#b10){ref-type="ref"}, [^11^](#b11){ref-type="ref"}, [^12^](#b12){ref-type="ref"}, [^13^](#b13){ref-type="ref"}, [^14^](#b14){ref-type="ref"} Of the 75 annotated genes, 28 genes have been previously analyzed by microarray ([Table 3](#t3){ref-type="table"}). The genes were either reported to be upregulated (*n* = 16), downregulated (*n* = 10) or variable (*n* = 2) depending on biopsy site assayed. There were 47 genes identified in this study that have not been previously described in the context of IBD investigations.

###### 

Genes identified by SSH in this study that have previously been associations with CD

  Genes symbol                   Study reference                                                                      Tissue site            Gene expression in CD   SSH clone abundance
  ------------------------------ ------------------------------------------------------------------------------------ ---------------------- ----------------------- ---------------------
  REG1A                          [10](#b10){ref-type="ref"}, [11](#b11){ref-type="ref"}, [12](#b12){ref-type="ref"}   Colon                  Upregulated             55
  [^13^](#b13){ref-type="ref"}   TI                                                                                   Downregulated                                  
  CEACAM5                        [^13^](#b13){ref-type="ref"}                                                         TI                     Upregulated             17
  CD74                           [^8^](#b8){ref-type="ref"}                                                           Colon                  Upregulated             12
  MMP2                           [^9^](#b9){ref-type="ref"}                                                           Sigmoid colon          Upregulated             12
  IGHG1                          [^9^](#b9){ref-type="ref"}                                                           Sigmoid colon          Upregulated             11
  PSME2                          [^14^](#b14){ref-type="ref"}                                                         Colon                  Upregulated             9
  IGL@                           [^11^](#b11){ref-type="ref"}                                                         Colon                  Upregulated             9
  REG1B                          [^12^](#b12){ref-type="ref"}                                                         Colon                  Upregulated             7
  LGALS4                         [^11^](#b11){ref-type="ref"}                                                         Colon                  Upregulated             5
  OLFM4                          [^13^](#b13){ref-type="ref"}                                                         All intestinal sites   Upregulated             5
  SERPINA1                       [^8^](#b8){ref-type="ref"}                                                           Colon                  Upregulated             4
  GBP1                           [^13^](#b13){ref-type="ref"}                                                         All intestinal sites   Upregulated             4
  APOB                           [^13^](#b13){ref-type="ref"}                                                         All intestinal sites   Upregulated             4
  TI                             Downregulated                                                                                                                       
  CEACAM6                        [^13^](#b13){ref-type="ref"}                                                         TI                     Upregulated             3
  CANX                           [^11^](#b11){ref-type="ref"}                                                         Colon                  Upregulated             2
  ALDOB                          [^10^](#b10){ref-type="ref"}                                                         Intestinal mucosa      Upregulated             2
  HLA‐DRA                        [^8^](#b8){ref-type="ref"}                                                           Colon                  Upregulated             1
  DMBT1                          [10](#b10){ref-type="ref"}, [13](#b13){ref-type="ref"}                               All intestinal sites   Upregulated             1
  SRGN                           [^12^](#b12){ref-type="ref"}                                                         Colon                  Upregulated             1
  EIF4EBP2                       [^13^](#b13){ref-type="ref"}                                                         TI                     Downregulated           5
  SLC5A1                         [^13^](#b13){ref-type="ref"}                                                         TI                     Downregulated           4
  TGOLN2                         [^13^](#b13){ref-type="ref"}                                                         TI                     Downregulated           3
  ANPEP                          [8](#b8){ref-type="ref"}, [12](#b12){ref-type="ref"}                                 Colon                  Downregulated           2
  UGT2B17                        [^13^](#b13){ref-type="ref"}                                                         TI                     Downregulated           2
  HIST1H1B                       [^13^](#b13){ref-type="ref"}                                                         All intestinal sites   Downregulated           1
  TTRAP                          [^13^](#b13){ref-type="ref"}                                                         TI                     Downregulated           1
  LAPTM5                         [^13^](#b13){ref-type="ref"}                                                         TI                     Downregulated           1
  GDA                            [^13^](#b13){ref-type="ref"}                                                         TI                     Downregulated           1

CD, Crohn\'s disease; SSH, suppressive subtractive hybridization; TI, terminal ileum.
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**Gene networks. ** To identify biological and functional networks based on potential gene interactions among the 75 SSH enriched genes, we utilized the "Core" program of the Ingenuity Pathway Analysis Software. The majority of the 75 genes were classified into six networks comprising the following functions: (i) antigen presentation, inflammatory response, cancer; (ii) cancer, cell cycle, cellular compromise; (iii) connective tissue development and function, tissue morphology, developmental disorder; (iv) infection mechanism, genetic disorder, nutritional disease; (v) cell signaling, cellular assembly and organization, cellular function and maintenance; and (vi) amino acid metabolism, molecular transport, small molecule biochemistry ([Table 4](#t4){ref-type="table"}).

###### 

Gene networks represented by suppressive‐subtractive‐hybridization‐enriched genes

  Gene network   Top functions                                                                           Genes involved                                                                                                                                                         Number of genes
  -------------- --------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------
  1              Antigen presentation, inflammatory response, cancer                                     ANPEP, APOB, CANX, CD74, CEACAM5, CEACAM6, CTSS, DDC, DMBT1, GBP1, HLA‐DRA, IGHG1, ITGB1, LGALS4, MMP2, OLFM4, PARP9, PSME2, PTMA, SERPINA1, SLC5A1, TGOLN2, UGT2B17   23
  2              Cancer, cell cycle, cellular compromise                                                 C12ORF35, DOCK9, EVL, GBP3, HIST1H1B, LAPTM5, LPHN1, MACF1, MAN1A1, MARK3, OTUD4, PABPC1, PRKCSH, SRGN, TUBA1B                                                         15
  3              Connective tissue development and function, tissue morphology, developmental disorder   ALDOB, APH1A, CAP1, EIF4EBP2, GUF1, HNF4G, RBM17, REG1A, REG1B, SF3B1, STOM, TTRAP, TMEM66, XRN1                                                                       14
  4              Infection mechanism, genetic disorder, nutritional disease                              APPBP2, CLCA1, CRIM1, HSD11B2, IGL@, NACA, PLS1, SCP2, SLC26A3                                                                                                         9
  5              Cell signaling, cellular assembly and organization, cellular function and maintenance   DNAJC5, EEF1A1, GDA, NRF1, PLCB3, PRKAA1, PSAP, VAV2                                                                                                                   8
  6              Amino acid metabolism, molecular transport, small molecule biochemistry                 SLC17A7                                                                                                                                                                1

Network 1 contained the highest number of SSH genes. Interestingly, 18/23 genes in this network have been previously reported in microarray studies. The five newly identified genes within this network are cathepsin (*CTSS*), DOPA decarboxylase (*DDC*), integrin beta 1 (*ITGB1*), poly ADP‐ribose polymerase (*PARP9*) and prothymosin alpha (*PTMA*). [Figure 2](#f2){ref-type="fig"} depicts a schematic representation of this gene network. *CTSS* and *ITGB1* appear to be involved in multiple pathways, including several direct and indirect associations with the previously reported genes.

![Gene network containing antigen presentation, inflammatory response and cancer as top functions. Genes enriched by suppressive subtractive hybridization (SSH) are highlighted in red, blue and green, while the other molecules serve as intermediates in the gene interactome. Genes previously reported as upregulated (red) in Crohn\'s disease (CD) population are closely associated with inflammatory proteins, such as major histocompatibility complex (MHC) class II complex, NF‐κB complex and 26S proteasome. Genes previously reported as downregulated (blue) in CD population are either indirectly activated by interferon‐α and interleukin (IL)‐1, or indirectly associated with ITGB1. Of the new genes identified (highlighted green), *CTSS* and *ITGB1* appear to be involved in multiple pathways within the inflammatory network. The different interactions include direct (solid lines) or indirect (dashed lines) interactions; binding (straight line), activation (arrow), inhibition (truncated line) or either activation or inhibition (truncated line with arrow).](JGH-27-1083-g002){#f2}
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**Genes associated with microbial pathogenesis. ** To elucidate evidence for microbial pathogenesis, the 75 functionally annotated genes were individually searched against the NCBI Entrez Gene database for reported functional associations with viral or bacterial infections. A total of 29 genes associated with microbial pathogenesis were identified ([Table 5](#t5){ref-type="table"}).

###### 

Differentially expressed genes associated with microbial pathogenesis

  Gene symbol   Gene name                                                                                         Function
  ------------- ------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ANPEP         Alanyl (membrane) aminopeptidase                                                                  Receptor for human coronavirus 229E[^27^](#b27){ref-type="ref"}
  CEACAM6       Carcinoembryonic antigen‐related cell adhesion molecule 6 (non‐specific cross reacting antigen)   Receptor for adherent invasive *Escherichia coli*, abnormally expressed by ileal epithelial cells in Crohn\'s disease patients[^28^](#b28){ref-type="ref"}
  ITGB1         Integrin beta 1                                                                                   Receptor for *Kaposi sarcoma herpesvirus* KSHV.HHV8, and *Helicobacter pylori*, promotes infection by human metapneumovirus[^29^](#b29){ref-type="ref"}
  CD74          CD74 molecule, major histocompatibility complex, class II invariant chain                         CD74 receptor facilitates the adhesion of *H. pylori* to gastric epithelial cells[^30^](#b30){ref-type="ref"}
  TTRAP         TRAF and TNF receptor associated protein                                                          Facilitates lentiviral integration[^31^](#b31){ref-type="ref"}
  DMBT1         Deleted in malignant brain tumors 1                                                               Facilitator of HIV‐1 transcytosis, broad bacterial‐binding specificity (LRR) inhibits LPS‐induced TLR4‐mediated NF‐kappaB activation[^32^](#b32){ref-type="ref"}
  TUBA1B        Tubulin, alpha 1b                                                                                 HIV‐1 binding to CD4 permissible cells induce acetylation of tubulin, facilitating HIV cell fusion, involved in EPEC and EHEC infection[^33^](#b33){ref-type="ref"}
  CTSS          Cathepsin S                                                                                       Mammalian reoviruses utilize CTSS for disassembly of the virus outer capsid and activation of the membrane penetration machinery[^34^](#b34){ref-type="ref"}
  NRF1          Nuclear respiratory factor 1                                                                      *Human T lymphotropic virus type 1* transactivates the promoter for T cell tropic HIV‐1 through association with NRF[^35^](#b35){ref-type="ref"}
  MAN1A1        Mannosidase, alpha, class 1A, member 1                                                            Processing of gp160 of HIV[^36^](#b36){ref-type="ref"}
  EEF1A1        Eukaryotic translation elongation factor 1 alpha 1                                                Interacts with hepatitis deltavirus RNA and HIV gag protein, possibly permitting packaging of viral RNA into virion[^37^](#b37){ref-type="ref"}
  TGOLN2        Trans‐golgi network protein 2                                                                     Involved in the final envelopment of herpesviruses[^38^](#b38){ref-type="ref"}
  CANX          Calnexin                                                                                          Interacts with measles virus protein F and hemagglutinin[^39^](#b39){ref-type="ref"}
  MMP2          Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase)           HIV‐1 induces MMP2 expression in astrocytes[^40^](#b40){ref-type="ref"}
  SERPINA1      Serpin peptidase inhibitor, clade A (alpha‐1 antiproteinase, antitrypsin), member 1               Specifically induced in *Helicobacter pylori* infection, inhibitor of HIV replication[^41^](#b41){ref-type="ref"}
  OTUD4         OTU domain containing 4                                                                           Expressed only in HIV‐1 infected cell[^42^](#b42){ref-type="ref"}
  MACF1         Microtubule‐actin cross‐linking factor 1                                                          Parvovirus infection induces the upregulation of MACF1[^43^](#b43){ref-type="ref"}
  PLS1          Plastin 1 (I isoform)                                                                             PLS1 is upregulated in HIV‐1‐infected human monocyte‐derived macrophages[^44^](#b44){ref-type="ref"}
  MUC17         Mucin 17                                                                                          MUC17 is upregulated upon infection by atypical enteropathogenic *Escherichia coli* [^45^](#b45){ref-type="ref"}
  CLCA1         Chloride channel accessory 1                                                                      CLCA1 plays a role in bacterial‐induced mucus hypersecretion[^46^](#b46){ref-type="ref"}
  EIF4EBP2      Eukaryotic translation initiation factor 4E binding protein 2                                     Adenovirus infection inactivates translational inhibitors 4E‐BP1 and 4E‐BP2[^47^](#b47){ref-type="ref"}
  SLC5A1        Solute carrier family 5 (sodium/glucose cotransporter), member 1                                  HIV Tat induces SGLT1 mis‐sorting and impairs intestinal glucose absorption[^48^](#b48){ref-type="ref"}
  PABPC1        Poly(A) binding protein, cytoplasmic 1                                                            Rotavirus nsp3 expression directs PABC1 from cytoplasm to nucleus, in poliovirus, cleavage of PABP contributes to viral translation shutoff that is required for the switch from translation to RNA replication[^49^](#b49){ref-type="ref"}
  SF3B1         Splicing factor 3b, subunit 1, 155 kDa                                                            Vpr, the viral protein R of HIV‐1, induces G(2) cell cycle arrest and apoptosis in mammalian cells via binding to a subunit of multimeric SF3B[^50^](#b50){ref-type="ref"}
  PSME2         Proteasome (prosome, macropain) activator subunit 2 (PA28 beta)                                   Upregulates presentation of viral MHC 1[^51^](#b51){ref-type="ref"}
  PTMA          Prothymosin, alpha                                                                                Inhibitor of HIV‐1 expression[^52^](#b52){ref-type="ref"}
  HLA‐DRA       Major histocompatibility complex, class II, DR alpha                                              Particular HLA class II region haplotypes affect the probability that an HBV infection will become persistent[^53^](#b53){ref-type="ref"}
  LRRC25        Leucine rich repeat containing 25                                                                 Contains motifs involved in bacterial LPS recognition
  XRN1          5′‐3′ exoribonuclease 1                                                                           XRN1 possess strong anti‐RNA virus activity by degrading uncapped RNA[^54^](#b54){ref-type="ref"}

EHEC, enterohaemorrhagic *Escherichia coli*; EPEC, enteropathogenic *Esherichia coli*; HBV, hepatitis B virus; LPS, lipopolysaccharide; LRR, leucine rich region; MHC, major histocompatibility complex; NRF, nuclear respiratory factors; OUT, operational taxonomic unit; PABP, poly A binding protein; TNF, tumor necrosis factor; TRAF, tumour necrosis factor receptor---associated factor 1.

Discussion {#ss18}
==========

The pathogenesis of CD is thought to involve a complex interplay between the microbiome, the environment and multiple genetic factors. To gain further insights into the gene regulation processes involved, several gene array analyses have been performed using surgical resections or endoscopic biopsies of the colon obtained during treatment of adults with known IBD.[^8^](#b8){ref-type="ref"}, [^9^](#b9){ref-type="ref"}, [^10^](#b10){ref-type="ref"}, [^11^](#b11){ref-type="ref"}, [^12^](#b12){ref-type="ref"}, [^14^](#b14){ref-type="ref"} However, the chronicity of the disease process and variability of treatments used are likely to have influenced gene expression profiles in these patients. Our study used tissue obtained at initial diagnosis in treatment‐naive children with early onset disease. To date, there have been very few studies of events at the genetic level during early disease onset in children. A recent study examining the genome‐wide expression profile of pediatric IBD patients was conducted using colonic tissue.[^8^](#b8){ref-type="ref"}

Our study extends these initial gene expression profile studies by comparing ileal biopsies from a pediatric cohort of CD and non‐IBD patients. SSH analysis led to the identification of 75 functionally annotated genes, specific to the CD cohort. Comparison of our SSH data with existing microarray studies revealed that 47 of these genes are novel and 28 genes have been previously identified by microarray to be either upregulated or downregulated in the CD population.

 {#ss19}

**Gene networks. ** The antigen presentation, inflammatory response and cancer gene network (Network 1) comprise one‐third of the genes identified by SSH, with a high proportion of genes previously identified to be differentially expressed in CD. This is partially attributable to acute inflammation of the biopsies of CD patients as compared with the non‐inflamed biopsies of non‐IBD controls. Differences in gene expression profiles between inflamed and non‐inflamed CD terminal ileum have been recently described.[^13^](#b13){ref-type="ref"} Relative to non‐IBD controls, the gene expressions of IL‐8 and SAA1 were reportedly much higher in inflamed CD terminal ileum as compared to non‐inflamed CD terminal ileum.[^13^](#b13){ref-type="ref"}

New genes identified within this network include *CTSS, DDC, ITGB1, PARP9* and *PTMA*. Based on the molecular interactions depicted in this network, *CTSS* and *ITGB1* appear to be involved in multiple pathways associated with inflammatory complexes (major histocompatibility complex \[MHC\] class II complex and NF‐κB complex), and with other genes previously reported as upregulated in CD population. CTSS is mainly expressed in antigen‐presenting cells and is required for the degradation of MHC‐class‐II‐associated invariant chains, necessary for proper MHC class II antigen presentation.[^55^](#b55){ref-type="ref"}, [^56^](#b56){ref-type="ref"} Integrins, which include ITGB1, are membrane receptors involved in cell adhesion and several processes, including immune response. ITGB1 is expressed during hypoxic conditions, and can serve as an indicator of intestinal wound repair, which occurs only in a hypoxic environment.[^57^](#b57){ref-type="ref"}

 {#ss20}

**REG1A and MMP2 expression. ** The *REG1A* gene is involved in regulation of cell proliferation, and has been proposed to function as a mitogenic and/or an anti‐apoptotic factor in ulcerative colitis (UC)‐colitic cancer progression.[^58^](#b58){ref-type="ref"} Its high expression levels have been correlated with the severity of intestinal inflammation in patients with UC, and microarray studies have reported its upregulation in the colon of adult IBD patients.[^9^](#b9){ref-type="ref"}, [^10^](#b10){ref-type="ref"}, [^12^](#b12){ref-type="ref"} Similarly, we identified an upregulation of *REG1A* in the terminal ileum of pediatric CD patients. This was however contrary to a recent study comparing the expression of *REG1A* in the terminal ileum of adult CD and non‐IBD controls, which reported a downregulation in *REG1A* expression.[^13^](#b13){ref-type="ref"} The difference in *REG1A* expression could indicate a distinction between the pathogenesis of early onset CD and adult‐onset CD. Based on the knowledge that *REG1A* gene expression is associated with cancer development,[^59^](#b59){ref-type="ref"} the high level of *REG1A* expression in the terminal ileum of some CD pediatric patients could indicate an increased risk for colorectal cancer development. Individuals with early onset CD have been previously described to have an increased risk of developing colorectal cancer.[^60^](#b60){ref-type="ref"}

The increased levels of MMP2 observed in CD ileum are consistent with previous studies conducted on colonic tissue where MMP2 is highly expressed in the intestinal epithelia during IBD.[^61^](#b61){ref-type="ref"}, [^62^](#b62){ref-type="ref"} Other studies have suggested the involvement of MMP2 in the regulation of epithelial barrier function.[^25^](#b25){ref-type="ref"} Since epithelial barrier dysfunction plays a central role in the pathogenesis of intestinal inflammation, the increased expression of MMP2 may serve as a response to counteract tissue damage, hence protecting against colitis.[^63^](#b63){ref-type="ref"}

The fluctuation in *REG1A* and *MMP2* gene expression between ileal biopsies of different patients and also between biopsies taken at different ileal locations of the same patient, suggest a spatial‐temporal nature of gene regulation during early CD pathogenesis. This finding is consistent with the clinical nature of CD, with its patchy distribution.

 {#ss21}

**Microbial associations. ** Twenty‐nine of the 75 genes identified in this study have functional roles in the processes of bacterial or viral infection. Evidence of host response in facilitating viral infection is demonstrated by the enrichment of gene products involved in viral attachment (ANPEP, ITGB1), viral entry, vesicular trafficking and transcytosis of viral proteins (TUBA1B, DMBT1, CTSS); lentiviral integration (TTRAP); viral translation (PABPC1, EIF4EBP2) and replication (NRF1); virion glycoprotein processing (MAN1A1); packaging (TGOLN2, EEF1A1) and possibly release (CANX). Evidence of response to bacterial infection is reflected by the enrichment of receptors for adherent invasive *Escherichia coli* and *Helicobacter pylori* (CEACAM6, CD74).[^28^](#b28){ref-type="ref"}, [^30^](#b30){ref-type="ref"}

The enrichment of *MMP2, SERPINA1, OTUD4, MACF1, PLS1, MUC17* and *CLCA1* transcripts suggests the presence of infectious agent(s) early in disease pathway as these genes have previously been reported to be upregulated during bacterial or viral infections.[^40^](#b40){ref-type="ref"}, [^41^](#b41){ref-type="ref"}, [^42^](#b42){ref-type="ref"}, [^43^](#b43){ref-type="ref"}, [^44^](#b44){ref-type="ref"}, [^45^](#b45){ref-type="ref"}, [^46^](#b46){ref-type="ref"} The involvement of SLC5A1 and SF3B1 gene products in the impairment of intestinal glucose absorption and apoptosis due to HIV‐1‐induced glucose channel mis‐sorting and cell cycle arrest suggest the occurrence of viral activities in early CD pathogenesis.[^48^](#b48){ref-type="ref"}, [^50^](#b50){ref-type="ref"} The *PSME2, PTMA, HLA‐DRA, LRRC25* and *XRN1* genes or gene products have been previously reported to be associated with defense against viral and bacterial infections.[^51^](#b51){ref-type="ref"}, [^52^](#b52){ref-type="ref"}, [^53^](#b53){ref-type="ref"}, [^54^](#b54){ref-type="ref"} It is possible that these genes are differentially expressed in CD patients in response to infectious triggers.

Our study recognizes the limitation of the SSH technique whereby the CD subtraction library contained clones that are not differentially expressed, as shown by the *ANPEP* expression data. This limitation was also observed in previous studies.[^15^](#b15){ref-type="ref"} Preliminary SSH data presented in this study were verified either by real‐time PCR quantification or comparison to microarray data from studies performed on individuals with and without IBD. Several of the genes anecdotally identified in the context of CD by our study have roles in microbial pathogenesis, promoting inflammation, epithelial remodeling, vesicular transport or cell differentiation and proliferation. These processes are relevant to CD pathogenesis, hence future investigations into the association between these novel gene candidates and CD could contribute to the understanding of the disease.

Supporting information
======================

**Figure S1** Suppressive subtractive hybridization method. Restriction endonuclease‐digested tester DNA was split into two pools and ligated with Adaptor 1 or Adaptor 2R. Two successive rounds of hybridization with excess restriction endonuclease‐digested driver DNA followed. Thereafter, single‐stranded components of the adaptors were filled in. Exponential amplification of tester‐specific sequences is used to enrich for potential differentially expressed genes. Type **a** molecules are significantly enriched, differentially expressed sequences, while cDNA that are not differentially expressed form type **c** molecules with the driver. The concentration of high‐ and low‐abundance sequences is equalized, whereby highly abundant molecules re‐anneal to form type **b** and **d** molecules. During the second hybridization, remaining equalized and subtracted single‐stranded tester cDNA reassociate to form type **e** hybrids, with different ends corresponding to sequences of Adaptor 1 and Adaptor 2R (adapted from Clontech PCR‐Select cDNA subtraction kit user manual \[BD Biosciences\]).

**Table S1** Primers used for real‐time reverse transcription polymerase chain reaction quantification of *ANPEP, REG1A, MMP2* and *RPL32*

**Table S2** Differentially expressed genes specific to Crohn's Disease (CD) ileum. Genes within each functional category are listed in order of clone abundance
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